Navigation Links
Mindray Announces First Quarter 2013 Financial Results
Date:5/6/2013

s regarding demand for our products; our ability to expand our production, our sales and distribution network and other aspects of our operations; our ability to stay abreast of market trends and technological advances; our ability to effectively protect our intellectual property rights and not infringe on the intellectual property rights of others; our ability to settle disputes with our customers and suppliers; competition in the medical device industry in China and internationally; and general economic and business conditions in the countries in which we operate. For a discussion of other important factors that could adversely affect our business, financial condition, results of operations and prospects, see "Risk Factors" beginning on page 5 of our annual report on Form 20-F which was filed with the Securities and Exchange Commission on April 8, 2013. Our results of operations for the first quarter as of March 31, 2013 are not necessarily indicative of our operating results for any future periods. The financial information contained in this release should be read in conjunction with the consolidated financial statements and notes thereto included in our public filings with the Securities and Exchange Commission. Any projections in this release are based on limited information currently available to us, which is subject to change. Although such projections and the factors influencing them will likely change, we will not necessarily update the information. Such information speaks only as of the date of this release.

All references to "shares" are to our ordinary shares, which are divided into two classes, Class A and Class B. Each of our American Depositary Shares, which trade on the New York Stock Exchange, represents one Class A ordinary share.

About Mindray We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain our global headquarters in Shenzhen, China, U.S. headquarters in 
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Mindray to Report First Quarter 2013 Financial Results on May 6, 2013
2. Mindray Medical to Exhibit New Products at 69th China International Medical Equipment Fair
3. Mindray Announces 2012 Fourth Quarter and Full Year Results
4. Mindray to Report Fourth Quarter and Full Year 2012 Financial Results on February 25, 2013
5. Mindray to Hold Annual General Meeting in Hong Kong on December 28, 2012
6. Mindray to Showcase Enhancements to DC-8 Ultrasound System at RSNA
7. Mindray DS USA, Inc. has Initiated a Voluntary Recall Affecting the A3/A5 Anesthesia Delivery System
8. Mindray Medical Announces Top Management Change
9. Mindray Medical to Participate in MEDICA 2012 in Dusseldorf, Germany
10. Mindray Announces Second Quarter 2012 Financial Results
11. Mindray to Report Second Quarter 2012 Financial Results on August 6, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 Future Market ... titled, "Continuous Glucose Monitoring Systems Market: Global Industry Analysis ... report, the global continuous glucose monitoring systems market was ... expected to reach US$ 788.4 Mn by 2020, registering ... to 2020. Global continuous glucose monitoring systems ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
(Date:7/30/2015)... , July 30, 2015  NanoSmart Pharmaceuticals, Inc., ... platforms, has received Orphan Drug Designation from the ... drug product that uses NanoSmart,s proprietary drug delivery ... dactinomycin for the treatment of Ewing,s sarcoma, a ... granted NanoSmart,s Orphan Drug Designation on the basis ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... 11 Phosphagenics,Limited ("Phosphagenics") (ASX: POH; AIM: PSG; ... their joint phase 2 human clinical,trial to establish ... of metabolic syndrome is advancing at three sites ... of study participants, the,double-blind phase 2 trial, which ...
... Feb. 11 ,Pharmion (Nasdaq: PHRM ) and ... Medicines Agency (EMEA) and the European Commission (EC),designated ... Orphan,Medicinal Product for the treatment of acute myelogenous ... require that the product be,intended for the treatment ...
Cached Medicine Technology:Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 2Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 3Update on Progression of Phosphagenics and Nestle Nutrition's Phospha E(R) Trial 4Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 2Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 3Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia 4
(Date:7/30/2015)... ... July 30, 2015 , ... ... entitled " Lovetraction Lines ." It's for women interested in improving their love ... desire. The course, which officially launched to the public early this morning, has ...
(Date:7/30/2015)... ... July 30, 2015 , ... The American Telemedicine Association ... and Tradeshow focused exclusively on telemedicine, telehealth and mHealth. The meeting, expected to ... will take place May 14-17, 2016 in Minneapolis, MN. , ATA’s annual meeting ...
(Date:7/30/2015)... ... July 30, 2015 , ... 24/7 Care At Home, a high-quality provider of ... announced that the Centers for Medicare and Medicaid (CMS) have awarded its agency the ... 24/7 Care At Home’s agency is one of three top Orange County agencies to ...
(Date:7/30/2015)... ... , ... Ross A. Clevens, MD, FACS has been reappointed by ... Surgery. This is Dr. Clevens’ second appointment by the prestigious school. Over ... strong presence and a valuable mentoring program for medical students. , ...
(Date:7/30/2015)... California (PRWEB) , ... July 30, 2015 , ... Western ... success of the 2015 Special Olympics World Games, the largest sports and humanitarian event ... the 1984 Olympic Games. , The World Games, held July 25 through August 2, ...
Breaking Medicine News(10 mins):Health News:Lovetraction Lines - Review Examining Simone Myers' New Online Course Released 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 2Health News:Presentation Proposals for ATA 2016 are Now Being Accepted Online at ATA2016.com 3Health News:24/7 Care At Home Earns a 5-Star Rating from the Centers for Medicare and Medicaid (CMS) 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 2Health News:Leading Melbourne Facial Plastic Surgeon Reappointed by UCF 3Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3
... North Carolina law firm sponsors bicycle safety video public service announcement ... ... February 17, 2009 -- HensonFuerst is giving local teens the chance ... announcement (PSA) contest in eastern North Carolina this spring. The mission ...
... CHICAGO, Feb. 17 While the common perception about ... is that it,s a rich person,s game, a Chicago ... eight years that we,ve been matching surrogates with our ... personal sacrifices. And nobody,s ever shown regret," says Robin ...
... Angeles Jewish Home are in it for the , Long ... Feb. 17 At the Los Angeles Jewish Home, one ... roof in the U.S. all agree on two things: They ... have the best ideas on just how to accomplish that ...
... Brighter smiles await,children in the Los Angeles area ... Oral Health Improvement Program to the La Canada,and Pacoima ... (Logo: http://www.newscom.com/cgi-bin/prnh/20011026/BIGLOTSLOGO ) , ... Smiles, Bright Futures dental van and its team,of dental ...
... that blocking the activity of a protein in the blood ... the study, normal mice and mice that had a genetically ... ultraviolet light that mimics chronic sun exposure. The mice that ... vascular skin cancer tumors than did the normal mice. , ...
... Michael Marmot, chair of the World Health Organization ... of the International Institute for Society and Health ... Positive Health Lecture Series talk, "Social Determinants of ... Health Lecture Series is organized by Martin Seligman, ...
Cached Medicine News:Health News:HensonFuerst Invites North Carolina Teens to Make Their Directorial Debuts 2Health News:The Surrogacy Journey: Not Just For the Wealthy 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 2Health News:Unique Group of 90-Year-Olds Share Top Ten Longevity Tips 3Health News:Colgate's Bright Smiles, Bright Futures Program Brings Free Children's Dental Screenings to Los Angeles Area Big Lots Stores 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 2Health News:Blocking protein leads to fewer, smaller skin cancer tumors 3Health News:Blocking protein leads to fewer, smaller skin cancer tumors 4
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
The PHOS method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of phosphorus in serum....
Medicine Products: